Experienced in Arthrogryposis Multiplex Congenita

Gina L. O'grady

Auckland, AUK, NZ 
Experienced in Arthrogryposis Multiplex Congenita
Auckland, AUK, NZ 
OverviewLocationsClinical Research

Overview

Gina O'grady practices in Auckland, New Zealand. Ms. O'grady is rated as an Experienced expert by MediFind in the treatment of Arthrogryposis Multiplex Congenita. Her top areas of expertise are CHARGE Syndrome, Tubular Aggregate Myopathy, Micrognathia, and Amyotonia Congenita.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Arthrogryposis Multiplex Congenita.

Gender
Female

Locations

Auckland, AUK, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Eteplirsen
Study Phase: Phase 3
View 1 Less Clinical Trial

34 Total Publications

Epidemiology of spinal muscular atrophy in Aotearoa-New Zealand.
Epidemiology of spinal muscular atrophy in Aotearoa-New Zealand.
Journal: Journal of neuromuscular diseases
Published: March 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. O'grady's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile